New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 27, 2020 - Neurocrine Biosciences announced the FDA approval of Ongentys (opicapone), as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Download PDF
Return to publications
